Literature DB >> 23639728

[Thymoma-associated myasthenia gravis: Clinical features and surgical results].

M Bouchikh1, H O El Malki, F Ouchen, A Achir, A Benosman.   

Abstract

OBJECTIVE: The aim of this study was to compare the characteristics of myasthenic patients with and without thymoma, and the results of thymectomy in both types of patients.
MATERIAL AND METHODS: A retrospective study was conducted among 66 patients who underwent thymectomy for myasthenia gravis in our department over a 10-year period (2000-2010). The surgical approach was sternotomy or anterolateral thoracotomy. Patients were divided into two groups according to the presence of thymoma: with (T-MG) and without (NT-MG) thymoma. Complete stable remission (CSR) was the primary endpoint.
RESULTS: Median age was 35.09±9.89 years. The NT-MG group had 38 patients (57.57%) and the T-MG group 28 patients (42.43%). There was no difference between the two groups regarding the surgical approach (P=0.52). T-MG patients were older (40.54±15.16 vs. 31.37±9.46) (P=0.008) and predominantly male. There were more generalized forms (P=0.01) and more bulbar involvement (P=0.02) in the T-MG group. The rate of CSR at 5 years was 7% and 17% in the T-MG and NT-MG patients respectively (P=0.70). At 10 years, it was 36% and 94.73% respectively (P=0.03).
CONCLUSION: Thymomatous myasthenia gravis is characterized by the severity of its clinical features. Remission rate at 10 years was significantly lower in the myasthenia with thymoma group.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chirurgie; Complete stable remission; Myasthenia gravis; Myasthénie; Rémission complète et stable; Surgery; Thymectomie; Thymectomy; Thymoma; Thymome

Mesh:

Year:  2013        PMID: 23639728     DOI: 10.1016/j.neurol.2013.01.625

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Outcomes after Thymectomy in Patients with Thymomatous Myasthenia Gravis.

Authors:  Sani Rabiou; Moussa Toudou-Daouda; Marwane Lakranbi; Ibrahim Issoufou; Yassine Ouadnouni; Mohamed Smahi
Journal:  J Neurosci Rural Pract       Date:  2022-03-09

2.  Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.

Authors:  ZhaoHui Luo; Ye Li; XiaoFang Liu; MengChuan Luo; LiQun Xu; YueBei Luo; Bo Xiao; Huan Yang
Journal:  BMC Med Genomics       Date:  2015-03-18       Impact factor: 3.063

3.  MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells.

Authors:  Hengxiao Lu; Hao Wang; Peidao Sun; Jiang Wang; Shuhai Li; Tongzhen Xu
Journal:  Cytotechnology       Date:  2021-05-07       Impact factor: 2.040

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.